Difference between revisions of "Angiosarcoma"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "==[https://www.nccn.org/ NCCN]==" to "==NCCN==") |
||
| (15 intermediate revisions by 2 users not shown) | |||
| Line 3: | Line 3: | ||
[[#top|Back to Top]] | [[#top|Back to Top]] | ||
</div> | </div> | ||
| − | {{#lst: | + | {{#lst:Editorial board transclusions|sarcoma}} |
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
| Line 12: | Line 12: | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
=Guidelines= | =Guidelines= | ||
| + | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' | ||
==[http://www.esmo.org/ ESMO]== | ==[http://www.esmo.org/ ESMO]== | ||
*[http://annonc.oxfordjournals.org/content/25/suppl_3/iii102.full.pdf+html Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014)] [https://pubmed.ncbi.nlm.nih.gov/25210080/ PubMed] | *[http://annonc.oxfordjournals.org/content/25/suppl_3/iii102.full.pdf+html Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014)] [https://pubmed.ncbi.nlm.nih.gov/25210080/ PubMed] | ||
| − | == | + | ==NCCN== |
| − | *[https://www.nccn.org/ | + | *''NCCN does not currently have guidelines at this granular level; please see [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1464 NCCN Guidelines - Soft Tissue Sarcoma].'' |
| + | |||
=All lines of therapy= | =All lines of therapy= | ||
==Bevacizumab monotherapy {{#subobject:3c01a5|Regimen=1}}== | ==Bevacizumab monotherapy {{#subobject:3c01a5|Regimen=1}}== | ||
| Line 36: | Line 38: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | #'''NU 04S1:''' Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan;24(1):257-63. Epub 2012 Aug 21. [https://doi.org/10.1093/annonc/mds237 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22910841/ PubMed] NCT00288015 | + | #'''NU 04S1:''' Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan;24(1):257-63. Epub 2012 Aug 21. [https://doi.org/10.1093/annonc/mds237 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22910841/ PubMed] [https://clinicaltrials.gov/study/NCT00288015 NCT00288015] |
==Paclitaxel monotherapy {{#subobject:6e2606|Regimen=1}}== | ==Paclitaxel monotherapy {{#subobject:6e2606|Regimen=1}}== | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen {{#subobject:ebf64d|Variant=1}}=== | ===Regimen {{#subobject:ebf64d|Variant=1}}=== | ||
| − | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
| − | ! style="width: | + | !style="width: 33%"|Study |
| − | ! style="width: | + | !style="width: 33%"|Dates of enrollment |
| + | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
|[https://doi.org/10.1200/jco.2008.17.3146 Penel et al. 2008 (ANGIOTAX)] | |[https://doi.org/10.1200/jco.2008.17.3146 Penel et al. 2008 (ANGIOTAX)] | ||
| + | |2005-04 to 2006-10 | ||
| style="background-color:#91cf61" |Phase 2 | | style="background-color:#91cf61" |Phase 2 | ||
|- | |- | ||
| Line 52: | Line 56: | ||
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15 | *[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15 | ||
====Supportive therapy==== | ====Supportive therapy==== | ||
| − | *[[Dexamethasone (Decadron)]] 8 mg IV once per day on days 1, 8, 15, prior to | + | *[[Dexamethasone (Decadron)]] 8 mg IV once per day on days 1, 8, 15, prior to paclitaxel |
| − | *[[Cimetidine (Tagamet)]] 200 mg IV once per day on days 1, 8, 15, prior to | + | *[[Cimetidine (Tagamet)]] 200 mg IV once per day on days 1, 8, 15, prior to paclitaxel |
| − | *[[Dexchlorpheniramine (Polaramine)]] 5 mg IV once per day on days 1, 8, 15, prior to | + | *[[Dexchlorpheniramine (Polaramine)]] 5 mg IV once per day on days 1, 8, 15, prior to paclitaxel |
*"Standard [[:Category:Emesis_prevention|antiemetics]] (mainly [[Metoclopramide (Reglan)]]) were prescribed as clinically indicated by the treating physician" | *"Standard [[:Category:Emesis_prevention|antiemetics]] (mainly [[Metoclopramide (Reglan)]]) were prescribed as clinically indicated by the treating physician" | ||
'''28-day cycle for 6 cycles''' | '''28-day cycle for 6 cycles''' | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | #'''ANGIOTAX:''' Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008 Nov 10;26(32):5269-74. Epub 2008 Sep 22. [https://doi.org/10.1200/jco.2008.17.3146 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/18809609/ PubMed] | + | #'''ANGIOTAX:''' Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008 Nov 10;26(32):5269-74. Epub 2008 Sep 22. [https://doi.org/10.1200/jco.2008.17.3146 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/18809609/ PubMed] EudraCT 2004-002841-12 |
| + | |||
==Pazopanib monotherapy {{#subobject:6hg776|Regimen=1}}== | ==Pazopanib monotherapy {{#subobject:6hg776|Regimen=1}}== | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> | ||
| Line 73: | Line 78: | ||
|2017-2019 | |2017-2019 | ||
| style="background-color:#1a9851" |Phase 3 (C) | | style="background-color:#1a9851" |Phase 3 (C) | ||
| − | |[[#Pazopanib_. | + | |[[#Pazopanib_.26_Carotuximab_999|Pazopanib & Carotuximab]] |
| style="background-color:#ffffbf" |Did not meet primary endpoint of PFS | | style="background-color:#ffffbf" |Did not meet primary endpoint of PFS | ||
|- | |- | ||
| Line 80: | Line 85: | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
| − | *[[Pazopanib (Votrient)]] 800 mg PO once per day | + | *[[Pazopanib (Votrient)]] 800 mg PO once per day on days 1 to 28 |
| − | ''' | + | '''28-day cycles''' |
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | #'''TAPPAS:''' Jones RL, Ravi V, Brohl AS, Chawla S, Ganjoo KN, Italiano A, Attia S, Burgess MA, Thornton K, Cranmer LD, Cheang MCU, Liu L, Robertson L, Adams B, Theuer C, Maki RG. Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial. JAMA Oncol. 2022 May 1;8(5):740-747. [https://doi.org/10.1001/jamaoncol.2021.3547 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8972152/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35357396/ PubMed] NCT02979899 | + | #'''TAPPAS:''' Jones RL, Ravi V, Brohl AS, Chawla S, Ganjoo KN, Italiano A, Attia S, Burgess MA, Thornton K, Cranmer LD, Cheang MCU, Liu L, Robertson L, Adams B, Theuer C, Maki RG. Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial. JAMA Oncol. 2022 May 1;8(5):740-747. [https://doi.org/10.1001/jamaoncol.2021.3547 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8972152/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/35357396/ PubMed] [https://clinicaltrials.gov/study/NCT02979899 NCT02979899] |
[[Category:Angiosarcoma regimens]] | [[Category:Angiosarcoma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Vascular sarcomas]] | [[Category:Vascular sarcomas]] | ||
Revision as of 11:36, 13 May 2024
| Section editor | |
|---|---|
 |
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN, USA |
3 regimens on this page
3 variants on this page
|
Note: this page contains regimens specific to angiosarcoma.
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
ESMO
- Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014) PubMed
NCCN
- NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Soft Tissue Sarcoma.
All lines of therapy
Bevacizumab monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Agulnik et al. 2012 (NU 04S1) | 2005-08 to 2011-04 | Phase 2 |
References
- NU 04S1: Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan;24(1):257-63. Epub 2012 Aug 21. link to original article contains dosing details in manuscript PubMed NCT00288015
Paclitaxel monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Penel et al. 2008 (ANGIOTAX) | 2005-04 to 2006-10 | Phase 2 |
Chemotherapy
- Paclitaxel (Taxol) 80 mg/m2 IV over 60 minutes once per day on days 1, 8, 15
Supportive therapy
- Dexamethasone (Decadron) 8 mg IV once per day on days 1, 8, 15, prior to paclitaxel
- Cimetidine (Tagamet) 200 mg IV once per day on days 1, 8, 15, prior to paclitaxel
- Dexchlorpheniramine (Polaramine) 5 mg IV once per day on days 1, 8, 15, prior to paclitaxel
- "Standard antiemetics (mainly Metoclopramide (Reglan)) were prescribed as clinically indicated by the treating physician"
28-day cycle for 6 cycles
References
- ANGIOTAX: Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008 Nov 10;26(32):5269-74. Epub 2008 Sep 22. link to original article contains dosing details in manuscript PubMed EudraCT 2004-002841-12
Pazopanib monotherapy
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Jones et al. 2022 (TAPPAS) | 2017-2019 | Phase 3 (C) | Pazopanib & Carotuximab | Did not meet primary endpoint of PFS |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.
References
- TAPPAS: Jones RL, Ravi V, Brohl AS, Chawla S, Ganjoo KN, Italiano A, Attia S, Burgess MA, Thornton K, Cranmer LD, Cheang MCU, Liu L, Robertson L, Adams B, Theuer C, Maki RG. Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial. JAMA Oncol. 2022 May 1;8(5):740-747. link to original article link to PMC article contains dosing details in manuscript PubMed NCT02979899